Peking University Cancer Hospital
Beijing's dedicated cancer hospital and the leading Chinese centre for gastric cancer trials, where claudin 18.2 CAR-T and PD-1 combinations were first tested in gastric disease.
Founded in 1976 as the Beijing Institute for Cancer Research, the hospital is Peking University's cancer centre and a national key clinical speciality in gastrointestinal oncology, gastric surgery, lymphoma, melanoma and sarcoma. Lin Shen's GI oncology department has led or co-led the pivotal Chinese trials of PD-1 antibodies in gastric and oesophageal cancer, the first-in-human claudin 18.2 CAR-T study (satricabtagene autoleucel with CARsgen), and early ADC programmes. Jun Guo's melanoma group defined the biology and treatment of acral and mucosal melanoma, which dominate in East Asia. The hospital runs a large phase 1 unit and the Beijing cancer registry.
- Gastric and oesophageal cancer
- Claudin 18.2 CAR-T
- Acral and mucosal melanoma
- Lymphoma
- Phase 1 unit
Led the CT041 trials that produced the first CAR-T therapy approved for a solid tumour, in gastric cancer.
First author of the CT041 trials that showed a CAR-T can shrink gastric and pancreatic tumours.
Pages like this
not linked directly; found by shared links- InstitutionHenan Cancer Hospital
Shares Oesophageal cancer, Diffuse large B-cell lymphoma, Gastric & gastro-oesophageal junction cancer, CAR-T cell therapy.
- InstitutionOlivia Newton-John Cancer Wellness and Research Centre
Shares Gastric & gastro-oesophageal junction cancer, Antibody-drug conjugate (ADC), Melanoma, Immune checkpoint inhibitors.
- IdeaIn vivo CAR-T against solid-tumour antigens
Shares Satricabtagene autoleucel, Claudin 18.2, Gastric & gastro-oesophageal junction cancer, CAR-T cell therapy.
- TrialCLARITY-Gastric 01
Shares Claudin 18.2, Oesophageal cancer, Gastric & gastro-oesophageal junction cancer, Antibody-drug conjugate (ADC).
- PairingCLDN18.2 antibody first line → CLDN18.2 ADC or CAR-T on progression
Shares Satricabtagene autoleucel, Claudin 18.2, Gastric & gastro-oesophageal junction cancer.
- Key paperCheckMate 649: nivolumab plus chemotherapy as first treatment for advanced gastric, gastro-oesophageal junction and oesophageal adenocarcinoma
Shares Lin Shen, Oesophageal cancer, PD-1, Gastric & gastro-oesophageal junction cancer.
- InstitutionTaipei Veterans General Hospital
Shares Gastric & gastro-oesophageal junction cancer, CAR-T cell therapy, Immune checkpoint inhibitors, Colorectal cancer.
- PersonYoon-Koo Kang
Shares Claudin 18.2, Sarcomas (soft tissue, bone, GIST), PD-1, Gastric & gastro-oesophageal junction cancer.